Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.

In this disease setting TG4010 showed a trend to benefit PFS at 6 months with rates of 44% for vaccinated versus 35% for controls (p= 0.13) and in terms of trends for benefit patient’s overall survival Stimuvax show a HR 0.74 with p = 0.112, Lucanix achieve a clinical response of 15% and better survival in the high-dose group, Racotumumab achieve numerical differences of 9.93 months for Vaccinated group vs. 4.53 months for Control group and CIMAvax EGF achieve 3.5 month of benefit for the subset of 60 years old and younger patients (Table 2 ).

also in 53,322 other papers